We are welcoming submissions to the following article collections.
Magnetic Resonance Spectroscopy: Advances Towards Clinical PracticeGuest Edited by David Cheng, Dyutika Kantamneni, and Mary Salvatore |
| Microbiome in the First 1000 Days of LifeGuest Edited by Souhaila Al Khodor |
|
|
Prevention and Early Diagnosis of Breast CancerGuest Edited by Monica Pernia Marin, Caren Greenstein, and Mary Salvatore |
This article collection aims to clarify the correlation between tissue fibrosis and cancer origination and progression.
This article collection focuses on the challenge of transferring the Mediterranean Diet key concept to non-Mediterranean areas within a “One Health” perspective.
We are recruiting new Associate Editors to join our international Editorial Board. Learn more about the role and how to apply here.
Get to know the Editors behind Journal of Translational Medicine!
This research study has identified that CAFs-derived lactate promoted GC progression and clarified its mechanism, proposing the H3K18la-ASPM-NCAPG axis. Daturilin could enhance the therapeutic efficacy of anti-PD-1 treatment. This offers innovative perspectives on the complex role of CAFs in the TME and the influence of lactate on tumor progression.
In this recent review, mesenchymal Stromal/Stem Cells (MSCs) are a cornerstone of regenerative medicine, prized for their versatility and therapeutic potential. This review article explores the most widely accepted methods for isolating MSCs from sources like bone marrow, adipose tissue, and umbilical cord, and outlines key criteria for their characterization—ensuring purity and functionality. By following established guidelines, researchers can unlock the full promise of MSCs in clinical applications.
Check out the most discussed articles from the previous month!
Journal of Translational Medicine has launched In Review, a new option that provides authors with on-demand information on the status of their manuscript, enables them to share their work with funders and their research community, and allows their colleagues to comment and collaborate - all whilst their manuscript is under review.
Read MoreIn this Q&A, Dr Florence Bietrix, Section Editor, talks to us about the importance of the journey from discovery to real-world application and how the Translational Process section is contributing directly to achieving the Sustainable Development Goals 3 (Good Health & Wellbeing), 5 (Gender Equality), and 10 (Reduced Inequalities).
In this Q&A, Dr Al Khodor discusses her career and research focus on women's and infants health, her efforts to contribute directly to achieving SDG3, and the Microbiome in the First 1000 Days of Life collection launch.
Journal of Translational Medicine is an open access journal publishing articles focusing on information derived from human experimentation so as to optimise the communication between basic and clinical science.
The journal covers all areas of translational medicine but also has several special sections:
|
|
|
Francesco (Franco) Marincola is the Chief Scientific Officer of Translational and Advanced Medicine (TAM) Biosciences, Nashville, TN. Franco brings over 30 years of research and development experience in immunology, oncology and cell therapy.
Most recently, Franco served as Chief Scientific Officer at Sonata Therapeutics, Boston, Massachusetts. Before he was Senior Vice President and Global Head of Research at Kite Pharma where he led the research organization to identify novel therapies for hematologic malignancies and solid tumors. Prior to Kite, he was President and Chief Scientific Officer at Refuge Biotechnologies, where he developed research strategies for adoptive cell therapy products and led therapeutic programs based on nuclease deactivated CRISPR circuits. Prior to Refuge, Franco was Distinguished Research Fellow in Immune Oncology at AbbVie, and Chief Research Officer at Sidra Medical and Research Centre.
Before joining the biopharma industry, Franco spent more than two decades at the National Institutes of Health (NIH) and National Cancer Institute (NCI), as a tenured senior investigator in cancer immunotherapy and biomarker research and as Chief Infectious Disease and Immunogenetics Investigator at the NIH Clinical Center.
Franco is the former President of the Society for Immunotherapy of Cancer (SITC). He currently serves as Editor-in-Chief for multiple peer-reviewed publications, including Journal of Translational Medicine, and Immunotherapy, and is the author of more than 700 peer-reviewed publications.
Franco is also a fiction writer and his collections can be found at:
https://wordpress.com/home/authorfrancomarincola.wordpress.com.
Franco received his M.D. from the University of Milan, Italy and completed his residency and training in immunology at Stanford University, California.
Citation Impact
Journal Impact Factor: 7.5 (2024)
5-year Journal Impact Factor: 7.0 (2024)
Source Normalized Impact per Paper (SNIP): 1.321 (2024)
SCImago Journal Rank (SJR): 1.997 (2024)
Speed
Submission to first editorial decision (median days): 11
Submission to acceptance (median days): 99
Usage 2024
Downloads: 7,617,512
Altmetric mentions: 6,383